Business Wire

VALBIOTIS

15.11.2021 07:37:09 CET | Business Wire | Press release

Share
Valbiotis Announces Positive Preclinical Results for TOTUM•070 in Hypercholesterolemia, Selected and Presented at the American Heart Association (AHA) Annual Meeting

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211114005021/en/

Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the selection of TOTUM•070's positive preclinical results in hypercholesterolemia by the annual meeting of the American Heart Association, the leading American learned society in the cardiovascular field.

Valbiotis is presenting two posters on TOTUM•070 at the AHA meeting, which is being held November 13-15, 2021, in virtual format. The results presented show a significant reduction in total cholesterol and particularly "bad" cholesterol (including LDL cholesterol)* , as well as initial data in favor of a multi-target mode of action on lipid metabolism. They support the potential of TOTUM•070, currently in Phase II of its clinical development against hypercholesterolemia. Recruitment has been completed and results are expected in the second quarter of 2022, with LDL cholesterol reduction as the primary endpoint.

TOTUM•070 is an innovative active substance based on a combination of 5 plant extracts (without phytosterols or red yeast rice), designed to reduce LDL cholesterol, a cardiovascular risk factor and the primary cause of atherosclerosis. It is developed for people with mild to moderate, untreated hypercholesterolemia.

The two studies presented at the AHA congress confirm the efficacy of TOTUM•070 on cholesterol and blood lipids and provide initial data on the mode of action of this active substance. In the two in vivo models explored, the work demonstrates that TOTUM•070 largely prevents hypercholesterolemia, with a dose-dependent reduction in "bad" cholesterol* of up to 47%. The first data on mode of action also reveal significant effects on several key mechanisms for the regulation of lipid metabolism, notably intestinal, hepatic and inflammatory.

This in-depth work is the result of close cooperation between Valbiotis' preclinical platform in Riom (Puy de Dôme) and Bruno GUIGAS' team at the University of Leiden (Netherlands), one of the Company's longstanding academic partners.

Pascal SIRVENT, Director of Discovery, Preclinical and Translational Research, member of the Valbiotis Board of Directors, comments: "These results on TOTUM•070 are striking in their consistency. First, they confirm a strong and dose-dependent preventive effect on blood cholesterol, the ultimate target of this active substance. Furthermore, they confirm the hypothesis of a multi-target mode of action on the regulation of lipid metabolism, a central objective of our plant-based approach. This is an important data set for the development and future commercialization of TOTUM•070 in hypercholesterolemia and a very promising signal for ongoing clinical studies. Their selection by the American Heart Association Congress is of course a great source of pride and recognition of the quality of the work done by our teams and those of the University of Leiden."

Bruno GUIGAS, Assistant Professor at the University of Leiden (Netherlands), adds:

"This research project had an exciting overall ambition for TOTUM•070, for the prevention of hypercholesterolemia. For our part, we focused on the intestinal mode of action of this active substance and demonstrated a significant effect on fat absorption. This is a particularly positive result on this well-known lever of lipid metabolism regulation. As an R&D partner of Valbiotis since 2015, we are very pleased with our contribution to the success of these joint projects, whose benefits and value are clearly demonstrated through their selection by the AHA Congress."

TOTUM•070 efficacy and mode of action results presented at AHA 2021

Both studies were conducted in two in vivo models, predictive of human pathophysiology, where hypercholesterolemia was induced by a high-fat diet. TOTUM•070 was administered according to a prevention protocol together with the high-fat diet. The design included two controls: one with a high-fat diet alone and the other with a normal diet. The first study was mainly oriented to efficacy objectives and tested TOTUM•070 at three different doses for 12 weeks. The second study, oriented to mode of action hypotheses, tested 2 different doses for 6 weeks. In both protocols, the results show a significant reduction of cholesterol levels by TOTUM•070 compared to a high-fat diet alone, confirming the preventive effect sought with this active substance.

The first study demonstrates a profound efficacy of TOTUM•070 on circulating lipids, with a dose-dependent reduction of 37-48% of "bad" cholesterol (non-HDL)* , 31-42% of total cholesterol as well as 30-46% of blood triglycerides, compared to the high-fat diet alone, after 12 weeks.

In terms of mode of action, the second study provided exploratory data indicating two major effects of TOTUM•070: reduction of intestinal absorption of lipids and reduction of their accumulation in the liver.

In both models, gene expression analyses also showed that TOTUM•070 administration normalized many markers involved in lipid metabolism as well as some pro-inflammatory markers, whereas they were strongly altered by a high-fat diet alone.

Link to the posters: https://www.valbiotis.com/en/publications/

About TOTUM•070

TOTUM•070 is an innovative active substance derived from food plant extracts, without phytosterols or red yeast rice, developed to act on lipid metabolism in people with hypercholesterolemia.

TOTUM•070 is currently being tested in a Phase II clinical trial, the HEART study, an international, multi-center, randomized, placebo-controlled study on 120 volunteers with mild to moderate hypercholesterolemia. Enrolment in this study was completed in September 2021 and results are expected in the second quarter of 2022.

At the end of its development, this new Health Nutrition product will be positioned in particular in people with LDL hypercholesterolemia, for levels up to 190 mg/dl, with a moderate overall cardiovascular risk. TOTUM•070 could be recommended to this large population for whom no drug therapy is currently recommended as first-line treatment, with the objective of reducing LDL cholesterol levels and thus the overall cardiovascular risk.

About Valbiotis

Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.

Its products are intended to be licensed to players in the health sector.

Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information about Valbiotis, please visit: www.valbiotis.com

Name: Valbiotis
ISIN code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150

1 "Bad" cholesterol is the non-HDL fraction of cholesterol. It includes ApoB lipoproteins, i.e. VLDL and LDL cholesterol.

This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document approved by the French Financial Markets Regulator (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website ( www.valbiotis.com ).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press release

Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. The Academy will support two-way knowledge exchange, bringing global expertise to Abu Dhabi while creating opportunities to share Abu Dhabi’s knowledge, expertise and innovation with the world. Inaugural course brought together senior leaders from government, healthcare, research, and industry with local and international scientific experts. Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life s

Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press release

Soracom suite combines existing platform services for physical AI, available worldwide Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, l

Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 15:23:00 CET | Press release

The raise follows the rapid growth of swaps, Variational’s new instrument bringing liquidity from traditional finance on-chain. Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in Se

Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 15:00:00 CET | Press release

Players Can Choose Their Quests, Developers Get Measurable Results From Their Games, and Advertisers Get Verified Insight From Players Who Choose to Share Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed

Sila Inks Long-Term Offtake Deal with Panasonic Energy to Power Domestic Battery Production18.11.2026 15:00:00 CET | Press release

Agreement to deliver Sila’s Titan Silicon® Si/C anode to Panasonic’s U.S. manufacturing sites, fortifying domestic battery supply chain resilience and advanced technology capabilities. Sila, a leading battery technology and materials company, today announced a commercial offtake agreement with Panasonic Energy Corporation of North America. The multi-year agreement is part of a long-term commercial relationship with the potential for over $1 billion of offtake over time. Sila will supply its proprietary Titan Silicon® silicon-carbon (Si/C) anode material from its Moses Lake, Washington plant to power Panasonic battery cells. The partnership is also expected to support significant manufacturing and construction job creation in the United States. With Sila’s U.S.-based anode production underpinned by proprietary American technology and know-how, Panasonic and its OEM customers gain a clearer path toward a more secure, resilient, and sustainable domestic supply chain. This press release fe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye